Lantern Pharma (LTRN) Corporate presentation summary

AI-driven drug development and technology platforms

• AI platforms RADRⓇ and withZeta.ai accelerate oncology drug discovery, reducing early-stage development timelines by 70% and costs by 80%.

• RADRⓇ predicts and stratifies clinical trial patients with 88% accuracy, supporting precision medicine.

• withZeta.ai integrates multi-agent reasoning and omics analytics, enabling rapid insights for rare cancer research and drug development.

• PredictBBB.ai predicts brain permeability of molecules with 94% accuracy, aiding CNS drug development.

• AI-driven platforms enable multi-dimensional molecular analysis and drug-likeness profiling.

Clinical pipeline and drug programs

• Ten disclosed drug programs, including LP-300 (NSCLC in never smokers), LP-184 (DDR-deficient solid tumors), and LP-284 (B-cell NHL and soft tissue sarcomas).

• LP-300 Phase 2 Harmonic™ trial shows 86% clinical benefit rate and durable responses in EGFR L858R NSCLC patients.

• LP-184 completed Phase 1a basket trial with robust safety and promising antitumor activity; plans for Phase 1b/2.

• LP-284 demonstrated complete metabolic response in a heavily pre-treated lymphoma patient in Phase 1a.

• STAR-001 (LP-184) for CNS cancers received Fast Track and Orphan Drug designations, with significant tumor reduction in preclinical models.

Market potential and designations

• Drug programs target markets exceeding $20 billion annually, including NSCLC, DDR-deficient solid tumors, and B-cell NHL.

• Multiple FDA designations: Fast Track, Orphan Drug, and Rare Pediatric Disease for LP-184, LP-284, and STAR-001.

• LP-184 and LP-284 have combination therapy potential with existing FDA-approved agents.